The long-term mortality remains unknown in women diagnosed with breast cancer in situ (BCIS). Here, we assessed the cause-specific mortality in BCIS patients. This population-based cohort study included 12,243 women diagnosed with BCIS in Sweden between 1980 and 2011. Patients were followed until death, emigration, or 31 December 2013, whichever came first. The 30-year cumulative incidence of breast cancer-specific mortality was 6.3%, which is considerably lower than 49.7% observed for other-cause mortality. Women diagnosed with BCIS were more likely to die from breast cancer (standardized mortality ratio [SMR], 3.85; 95% CI, 3.47-4.27) but less likely to die from cardiovascular disease (SMR, 0.88; 95% CI, 0.82-0.95) than women in the general population. Specifically, the SMRs for breast cancer-specific mortality decreased over time from 5.19 (95% CI, 3.95-6.81) among BCIS diagnosed during 1980-1989 to 3.03 (95% CI, 2.35-3.91) among those diagnosed during 2000-2011. Furthermore, higher risk of death from other causes was seen among those with older age at BCIS diagnosis, lower levels of education, nulliparity, higher Charlson Comorbidity Index, and being hospitalized before BCIS diagnosis; whereas, lower risk of death from breast cancer was seen among BCIS diagnosed in the later time period and those with younger age at first birth. We conclude that most women diagnosed with BCIS die from causes other than breast cancer, which highlights the need for actions not only to reduce nonbreast cancer mortality but also to identify patient where extensive curative BCIS treatment is not adding to survival.
Mammography screening may reduce the risk of invasive breast cancer [1] [2] [3] at the price of overdiagnosing breast cancer in situ (BCIS). [4] [5] [6] [7] [8] [9] A recent study has found that for every three screen-detected ductal carcinoma in situ (DCIS), there was one fewer invasive interval cancer in the next 3 years. 2 However, on the other hand, 1-50% of the screen-detected breast cancer have been estimated to be overdiagnosed. 1, [10] [11] [12] Therefore, actions should be taken not only to maximize the use of mammography screening, but also to minimize the numbers of overdiagnosis to prevent unnecessary treatment and suffering. 1, 4, 13 Overdiagnosis can be defined as a detection of BCIS in a person who will die from causes other than breast cancer. Based on this definition, whether overdiagnosis of BCIS will happen depends on both the risk of BCIS progression and the risk of dying from other causes. However, previous studies usually focused only on BCIS prognostic factors without considering the factors that might increase the risk of death from other causes, 14, 15 thus provided limited information regarding the potential risk of overdiagnosis.
In this study, we aimed to investigate the cause-specific mortality in women diagnosed with BCIS, with specific objectives including: (i) to calculate the 30-year cumulative incidence of cause-specific mortality in BCIS patients; (ii) to identify factors that predict higher risk of death from other causes but lower risk of death from breast cancer in BCIS patients; (iii) to calculate standardized mortality ratios (SMRs) of BCIS by age at diagnosis, calendar years of diagnosis, and years since diagnosis; and (iv) to investigate the calendar change in the treatment of BCIS. For comparison, we also examined the cause-specific mortality and treatment in women diagnosed with invasive breast cancer.
Material and Methods

Data sources
This study was based on six Swedish nationwide registers, namely the Swedish Cancer Register, the Inpatient Register, the Multigeneration Register, the Total Population Register, the Education Register, and the Emigration/Immigration Register. The Swedish Cancer Register has used a code for histological type (WHO/HS/CANC/24.1) since 1958 and it is compulsory by law in Sweden for every healthcare provider to report all newly detected cancer. 16 The unique Swedish Multigeneration Register includes information on parent-offspring relations for Swedish citizens born since 1932. 17 All the six registers cover the whole population of Sweden and have proved to be of high quality. [17] [18] [19] Record-linkage between different registers were made using the Personal Identification Number, a unique identifier assigned to all residents in Sweden. 20 In addition, to investigate the calendar change in the treatment of BCIS and invasive breast cancer, we also retrieved regional data from Stockholm-Gotland Breast Cancer Register.
Study population
A total of 20,666 women diagnosed with BCIS were reported to the Swedish Cancer Register between 1980 and 2011. Among them, we excluded 6,133 BCIS with synchronous invasive breast cancer (defined as invasive breast cancer diagnosed within 3 months), 21 
Statistical analysis
Patients were followed from the date of the cancer diagnosis until emigration, death, or 31 December 2013, whichever came first. The 30-year cumulative incidence of cause-specific mortality was graphically shown in a competing risks framework. Competing risk regression was also used to determine the predictors of cause-specific mortality in BCIS patients, after accounting for each other as the competing events. 23 The SMR was calculated by dividing the observed number of deaths by the expected number of deaths. The expected number of deaths was calculated by applying age-and calendar period-stratified person-years of observation to corresponding mortality rates in the general population. All statistical tests were two-sided with a significance level of p < 0.05. We used SAS software (v 9.4; SAS Institute Inc., Cary, NC) and Stata software (v 13.0; Stata Corporation, College Station, TX) for all statistical analysis. This study was approved by the Regional Ethical Reviewer Board in Stockholm, Sweden.
Results
Proportion of women dying from breast cancer
Among the 12,243 BCIS diagnosed between 1980 and 2011, 361 died from breast cancer, and 2,065 died from causes other than breast cancer over a mean of 12.5 years of follow up. The proportion of women dying from breast cancer decreased from 37% to 8% as age at BCIS diagnosis increased from 40-49 years to 70-74 years, from 24% to 18% as calendar year of BCIS diagnosis increased from 1980-1989 to 2000-2011, and from 20% to 6% as years of follow-up increased from 0-9 years to 20-29 years (Fig. 1 ).
Cumulative incidence of cause-specific mortality
The 10-, 20-, and 30-year cumulative incidence of death from breast cancer was 2.0%, 4.6%, and 6.3%, respectively, in women diagnosed with BCIS (Fig. 2) . The life-time risk of breast cancer mortality decreased with increasing age at diagnosis, from 9.0% among BCIS diagnosed at 40-50 years to 3.3% among those diagnosed at 70-74 years (Supporting Information Fig. S1 ). The 30-year cumulative incidence of death from causes other than breast cancer was 49.7% in BCIS patients, which could translate to 14.7% of death from other cancers, 18.0% of death from cardiovascular disease, and 17.0% of death from causes other than breast cancer or aforementioned diseases (Fig. 2) .
For comparison, the 30-year cumulative incidence of death from breast cancer was 27.0%, and the 30-year cumulative incidence of death from causes other than breast cancer was 47.7%, among women diagnosed with invasive breast cancer (Fig. 2) .
Predictors of cause-specific mortality
Higher risk of death from causes other than breast cancer was seen among patients who were older, less educated, What's new? Breast cancer screening saves lives by preventing invasive cancers, but how often are non-invasive cancers overdiagnosed? To investigate, these authors looked at how many women die of other causes after screening detects breast cancer in situ (BCIS). Using data collected on women diagnosed with BCIS between 1980-2011, they looked at cause of death over a 30-year period. Far more women died of something besides breast cancer: 50%, compared with just 6% who perished of breast cancer. While 6% is still higher than among the general population, these results do suggest that extensive BCIS treatments may not be prolonging survival.
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He et al. nulliparity, with higher Charlson Comorbidity Index, and being hospitalized before BCIS diagnosis (Table 1) . Lower risk of death from breast cancer was seen among patients who were younger at first childbirth and among BCIS patients diagnosed in the later time period (Table 2) .
Standardized mortality ratio
Women diagnosed with BCIS were more likely to die from breast cancer than women in the general population, with a SMR of 3.85 (95% CI, 3.47-4.27). Specifically, the SMRs decreased over age from 6.26 (95% CI, 5.14-7.62) among BCIS diagnosed at 40-49 years to 2.96 (95% CI, 2.52-3.49) among those diagnosed at 60-74 years, and decreased over time from 5.19 (95% CI, 3.95-6.81) among BCIS diagnosed during 1980-1989 to 3.03 (95% CI, 2.35-3.91) among those diagnosed during 2000-2011. By comparison, the SMRs for invasive breast cancer also decreased over age at BCIS diagnosis, years of BCIS diagnosis, and years since BCIS diagnosis (Fig. 3) .
Women diagnosed with BCIS were less likely to die from cardiovascular disease than women in the general population (SMR, 0.88; 95% CI, 0.82-0.95), especially within the first 10 years of follow-up (SMR, 0.83; 95% CI, 0.73-0.94). By comparison, women diagnosed with invasive breast cancer experienced higher risk of mortality from cardiovascular disease (SMR, 1.03; 95% CI, 1.01-1.05), mortality from other cancer (SMR, 1.12; 95% CI, 1.09-1.15), and mortality from causes other than breast cancer or aforementioned diseases (SMR, 1.15; 95% CI, 1.12-1.17), than women in the general population (Fig. 3) . 
Trends in the treatment of BCIS
The proportion of patients undergoing mastectomy decreased 1.3% annually for BCIS patients and 2.0% annually for invasive breast cancer patients, respectively, between 1980 and 2008. In contrary, the proportion of patients undergoing lumpectomy with radiotherapy increased 1.4% annually for BCIS patients and increased 2.1% annually for invasive breast cancer, respectively, between 1980 and 2008 (Fig. 4) .
Discussion
In this population-based cohort study, a 30-year cumulative incidence of 6.3% was observed for breast cancer mortality in BCIS patients, which is considerably lower than the 49.7% observed for other-cause mortality. Higher risk of death from other causes was seen among patients who were older, less educated, nulliparity, with higher Charlson Comorbidity Index, and being hospitalized before BCIS diagnosis; whereas, lower risk of death from breast cancer was seen among patients who were younger at first childbirth and BCIS diagnosed in the later time period. When compared with the general population, women diagnosed with BCIS were more likely to die from breast cancer, but less likely to die from cardiovascular disease. For comparison, women diagnosed with invasive breast cancer were more likely to die from breast cancer, cardiovascular disease, other cancers, and causes other than breast cancer or aforementioned diseases than women in the general population.
Nonbreast cancer death is the leading causes of death in women diagnosed with BCIS. Out of every nine deaths observed in BCIS patients during the 30 years of follow-up, eight deaths are attributed to causes other than breast cancer. This high proportion of death from other causes contradicts with the low awareness to reduce death from other causes in BCIS patients in the current practice. To address this issue, physician should not only counsel patients on BCIS treatment but also on modifying lifestyles to reduce the patients' risk of death from causes other than breast cancer. As women are more likely to be persuaded to change their lifestyles after a tumor diagnosis, 24 and most of the nonbreast cancer death observed in our study, such as cardiovascular diseases, were lifestyle-related, integrating lifestyle interventions into BCIS management can thus greatly improve the overall survival in BCIS patients. After the introduction of the biennially mammography screening to women aged 40-74 years, 25 the incidence of BCIS has increased 4-7-fold, representing now about 20% of all screen-detected breast cancer in Sweden. 26 Among them, a proportion of BCIS may never become life-threatening because only 20-30% of BCIS managed with biopsy alone will eventually progress into invasive cancer. 27 Despite this heterogeneity, 82.4% of patients with BCIS 20 mm underwent breast conserving surgery, and 72.7% of patients with BCIS 15 mm underwent radiation therapy in Sweden in 2012. 28 These facts together suggest that a proportion of BCIS patients may have been treated unnecessary for a 
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clinically insignificant disease, thus suffering from unnecessary surgical morbidity and radiation side effects. To prevent overtreatment, the risk of death from other causes should be considered because treatment is unnecessary if the BCIS patients were destined to die from causes other than breast cancer. However, previous studies usually focused only on breast cancer incidence/mortality without considering factors that might increase the risk of death from other causes.
14,15 Our study filled this knowledge gap and found that higher risk of death from other causes was found among patients who were older, less educated, nulliparity, with higher Charlson Comorbidity Index, and being hospitalized before BCIS diagnosis. These predictors identified in our study, together with predictors of lower risk of death from breast cancer, 14 can help to identify patients who are more likely to die from causes other than breast cancer, thus may Note: Death from other causes cumulated after accounting for death from breast cancer as the competing event. Variables were not included in the multivariable analysis if no significant associations were detected in the univariable analysis. The multivariable analysis adjusted for all variables retained in the column. Abbreviation: HR, hazard ratio; 95% CI, 95% confidence intervals; BCIS, breast cancer in situ.
have implications for treatment decision-making to prevent BCIS overtreatment. Age at diagnosis is the most important predictor for causes of death (due to breast cancer or due to other causes) in women diagnosed with BCIS. The proportion of women dying from breast cancer decreased from 37% among BCIS diagnosed at 40-49 years to only 8% among those diagnosed at 70-74 years. Older patients have relatively shorter life 
expectancy, thus may not live long enough to develop breast cancer. This hypothesis is supported by the fact that in our study, older patients had much higher risk of death from other causes but lower lifetime risk of death from breast cancer and lower SMRs for breast cancer-specific mortality when compared with younger patients. Therefore, overdiagnosis may be more common in older BCIS patients, especially if they had severe comorbidities and low-risk BCIS.
Calendar year of BCIS diagnosis is another predictor for causes of death in BCIS patients. The proportion of women dying from breast cancer decreased from 24% among women diagnosed in 1980-1989% to 18% among those diagnosed in 2000-2011. Consistently, the SMRs for breast cancer-specific mortality decreased over time, from 5.19 (95% CI, 3.95-6.81) among BCIS diagnosed during 1980-1989 to 3.03 (95% CI, 2.35-3.91) among those diagnosed during 2000-2011. These decreases may be explained by several hypotheses. First, the increased use of mammography screening after a BCIS diagnosis has made the detection of subsequent invasive cancer easier, thus may help to reduce the risk of death from breast cancer. Second, therapy for both BCIS and invasive breast cancer has improved over the years, 29 leading to fewer women with a previous BCIS being diagnosed with invasive breast cancer and fewer deaths after developing invasive breast cancer. Third, it is possible that the increased sensitivity of screening technology has led to the detection of more favorable BCIS, 30 which would reduce the risk of death from breast cancer.
Consistent with previous findings, 31 women diagnosed with BCIS are less likely to die from cardiovascular disease than women in the general population. This result is not surprising given that higher level of estrogen-which is an established risk factor for BCIS-has been suggested to provide protection against cardiovascular disease.
32 Furthermore, the reduced death from cardiovascular disease may also be due, at least in part, to a "healthy adherer" effect. That is, BCIS patients are more likely to be adherers of mammography screening, and adherers have been reported to be highly educated and more likely to perform healthy behaviors such as regular physical activity and nonsmoking, when compared with nonadherers. 33, 34 In contrary, women diagnosed with invasive breast cancer were more likely to die from cardiovascular disease than women in the general population. This heterogeneity may partially be due to the fact that radiotherapy-which has been reported to increase the risk of cardiovascular disease 35 -is more frequently used in invasive breast cancer than in BCIS. However, our results on cardiovascular disease mortality by laterality (left tumors vs. right tumors) did not adequately support the radiotherapy hypothesis, with a hazard ratio of 1.04 (95% CI, 1.00-1.09) for invasive breast cancer and 1.07 (95% CI, 0.93-1.25) for BCIS.
The patterns of SMRs for breast cancer-specific mortality differ considerably between BCIS and invasive breast cancer. The SMRs remained constant among BCIS patients, but decreased with increasing years of follow-up among invasive breast cancer patients. Furthermore, during the 20-29 years of follow-up, the SMRs for BCIS and invasive breast cancer was 3.05 (95% CI, 2.06-4.51) and 8.42 (95% CI, 7.78-9.10), respectively. Since most invasive breast cancer patients who can survive 20 years are likely to be early-stage invasive breast cancer, this difference raises concerns on the current use of similar treatment strategies for BCIS and early-stage invasive breast cancer. [36] [37] [38] [39] This study has several limitations. First, in the current practice, almost all BCIS were treated with mastectomy or breast conserving surgery with or without radiotherapy. 28, [36] [37] [38] [39] These therapies could affect not only the risk of death from breast cancer, but also death from other causes. 35, 40 Therefore, it is impossible to determine the causes of death in women diagnosed with BCIS if they were left untreated. Second, since the Swedish Cancer Register does not collect data on treatment, we were unable to investigate the impact of BCIS treatment on mortality. This limitation is minimized by the fact that different BCIS treatments have only small impact on breast cancerspecific mortality. 27 Finally, since the Swedish Cancer Register adopted the use of SNOMED histology only since 1993, 16 we were unable to distinguish DCIS from lobular carcinoma in situ (LCIS) for BCIS diagnosed between 1980 and 1993. This limitation is reduced by the fact that for BCIS diagnosed since1993, LCIS accounted for only 6% of BCIS in our study and further restricting our analysis to DCIS patients provided similar results as the main analysis (SMR In conclusion, over the 30 years of follow-up, the absolute risk of dying from breast cancer is low compared with BCIS patients' risk of dying from other causes, thus highlighting the need for actions not only to reduce nonbreast cancer mortality but also to identify patient where extensive curative BCIS treatment is not adding to survival. Predictors identified in our study can help to identify BCIS patients who are more likely to die from causes other than breast cancer, thus may have implications for treatment decision-making to prevent BCIS overtreatment.
